Literature DB >> 6635439

Chronic staphylococcal osteomyelitis: treatment with regimens containing rifampin.

C W Norden, J Fierer, R E Bryant.   

Abstract

Experience with rifampin as a component of combination antibiotic therapy for chronic staphylococcal osteomyelitis was reviewed. These data included the preliminary results of a randomized, prospective trial of parenteral nafcillin alone vs. parenteral nafcillin plus oral rifampin; the results of use of rifampin in combination with other oral antibiotics for the treatment of chronic staphylococcal osteomyelitis; and experience with rifampin regimens at the Oregon Health Sciences University. A total of 28 patients are described in this report; 70% of those who received regimens including rifampin experienced an apparent cure of infection. Most patients whose infections were not cured had inadequate surgical therapy or were also infected with other bacteria. Staphylococcus aureus was eradicated from the sinus drainage of all but one patient. Although these results are encouraging, a larger number of patients and a longer follow-up period are required for an adequate evaluation of the place of rifampin in therapy for chronic staphylococcal osteomyelitis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6635439     DOI: 10.1093/clinids/5.supplement_3.s495

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  13 in total

Review 1.  Animal models as predictors of the safety and efficacy of antibiotics.

Authors:  O Zak; T O'Reilly
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

2.  Antimicrobial therapy for bone and joint infections.

Authors:  Saima Aslam; Rabih O Darouiche
Journal:  Curr Infect Dis Rep       Date:  2009-01       Impact factor: 3.725

3.  In vitro antimicrobial effect against Streptococcus pneumoniae of adding rifampin to penicillin, ceftriaxone, or 1-ofloxacin.

Authors:  K P Giron; M E Gross; D M Musher; T W Williams; R A Tharappel
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

Review 4.  Systemic antibiotic therapy for chronic osteomyelitis in adults.

Authors:  Brad Spellberg; Benjamin A Lipsky
Journal:  Clin Infect Dis       Date:  2011-12-12       Impact factor: 9.079

5.  Systemic antimicrobial therapy in osteomyelitis.

Authors:  Henry S Fraimow
Journal:  Semin Plast Surg       Date:  2009-05       Impact factor: 2.314

6.  Dynamic PET-facilitated modeling and high-dose rifampin regimens for Staphylococcus aureus orthopedic implant-associated infections.

Authors:  Oren Gordon; Donald E Lee; Bessie Liu; Brooke Langevin; Alvaro A Ordonez; Dustin A Dikeman; Babar Shafiq; John M Thompson; Paul D Sponseller; Kelly Flavahan; Martin A Lodge; Steven P Rowe; Robert F Dannals; Camilo A Ruiz-Bedoya; Timothy D Read; Charles A Peloquin; Nathan K Archer; Lloyd S Miller; Kimberly M Davis; Jogarao V S Gobburu; Sanjay K Jain
Journal:  Sci Transl Med       Date:  2021-12-01       Impact factor: 17.956

7.  Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants.

Authors:  M Drancourt; A Stein; J N Argenson; A Zannier; G Curvale; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

8.  Enhanced elimination of ciprofloxacin after multiple-dose administration of rifampin to rabbits.

Authors:  S L Barriere; G W Kaatz; S M Seo
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

Review 9.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

10.  Enzyme-linked immunosorbent assay for detection of antibodies to Staphylococcus aureus cell walls in experimental osteomyelitis.

Authors:  E Jacob; D M Arendt; I Brook; L C Durham; M C Falk; S J Schaberg
Journal:  J Clin Microbiol       Date:  1985-10       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.